Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779402 · ClinicalTrials.gov registry record · Phase 3
PROvenge Treatment and Early Cancer Treatment
A Phase 3 study of Prostate Cancer, sponsored by Dendreon.
- Completed
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
- 18
- Study locations
NCT00779402 is a Phase 3 study of Prostate Cancer that has completed, run by Dendreon. The registered enrollment target is 176 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The trial reports 18 study locations across 11 states.
The verdict
NCT00779402, a Phase 3 study of Prostate Cancer, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
- 18
- Study locations
Study Summary
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US. The purpose of the study was to determine if sipuleucel-T was effective for treatment of early stage, non-metastatic prostate cancer. The study compared the active vaccine to control to determine whether the product delayed the time until cancer progression.
Conditions Studied
Interventions
- OTHER Control
- BIOLOGICAL Sipuleucel-T
Study Locations (18)
Oregon
- Providence Medical Center - Portland
- Oregon Health and Sciences University - Portland
- Oregon Urology Institute - Springfield
Pennsylvania
- Urology Health Specialists - Bryn Mawr - Bryn Mawr
- Albert Einstein Medical Building - Philadelphia
- Bryn Mawr Urology Group - Rosemont
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- South Orange County Medical Research - Laguna Hills
New York
- Mount Sinai School of Medicine - New York
- University of Rochester Medical Center - Rochester
Washington
- Virginia Mason Medical Center - Seattle
- Swedish Medical Center - Seattle
Colorado
- University of Colorado Health Sciences Center - Aurora
Illinois
- Oncology Specialists, SC - Park Ridge
North Carolina
- McKay Urology - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2001-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779402
The ClinicalTrials.gov registry entry for NCT00779402 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT00779402 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Oregon, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT00779402 about?
NCT00779402 is a clinical study titled "PROvenge Treatment and Early Cancer Treatment". The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US. The purpose of the study was to determine if sipuleucel-T was effective for treatment...
What is the current status of trial NCT00779402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2001-10. Estimated completion is 2015-05.
What conditions does trial NCT00779402 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00779402?
The interventions under investigation include: Control (OTHER), Sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00779402?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00779402 being conducted?
This trial has 18 study locations across California, Colorado, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.